Written by ι Stock Market Media Group Staff — September 10, 2014
Plandaí Biotechnology (OTCQB: PLPL) recently released the preliminary results from its human clinical trial where the company’s green tea extract, Phytofare™ Catechin Complex, was clinically tested and compared to a commercially available green tea extract. In the clinical trial, Plandaí’s Phytofare extract product showed greater bioavailability to participants than did the commercial extract by a factor of 10.
These results echo the USDA’s findings that were published in 2012. The USDA concluded that Plandaí’s proprietary extraction process for treating vegetable matter provides more bioavailability and more benefit to consumers. So, now in 2014, we’re presented with even more evidence that the extraction process delivers greater bioavailability with this clinical trial conducted in South Africa by North West University.
Plandaí’s extract has now shown in the preliminary results of a clinical trial that it can deliver more of what many believe makes green tea healthy. View the preliminary results: http://www.plandaibiotech.com/bioavailability_trial_preliminary_results.pdf
In an article written for WebMD, several researchers rave about the benefits of green tea, including, Beth Reardon, RD, a Boston nutritionist, who said of green tea’s biggest benefit, “It’s all about the catechin content.” Catechins are a type of antioxidant found in the greatest abundance in the leaves of the tea plant.
The article states that green tea has been shown to improve blood flow and lower cholesterol, and says a 2013 review of many studies found green tea helped prevent a range of heart-related issues, from high blood pressure to congestive heart failure.
For the health benefits of the green tea plant to be realized and to be beneficial, however, the catechins have to be absorbed into the body and then remain in the bloodstream long enough to be effective.
According to Professor Anne Grobler of North West University, Plandaí’s product showed that by using the company’s extraction process, which unzips and reconfigures the plant’s molecules to be more accepted by the human body, with Phytofare all 8 of the plant’s catechins were present in the bloodstream versus only 2 catechins detected in the bloodstream when the commercial extract was tested.
Additionally, the trial’s results found that when using the company’s technology, absorption of those catechins was 5 times greater, and the life span of the catechin’s molecules in the bloodstream was doubled in Phytofare when compared to that of the commercial green tea extract.
The significance of these results to Plandaí is that an extract that allows the body to experience more of the health benefits of green tea is expected to have a significant market advantage over traditional green tea products where most of the catechins are lost through metabolization before they ever enter the bloodstream. Simply put, Plandaí’s product delivers significantly more of the nutrients and then those nutrients remain in the bloodstream twice as long.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm offering a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is being compensated $3,500 per month by Plandai Biotechnology, Inc. for the creation of these materials. In the past, SMMG was compensated for similar activities by a third party. These prior activities occurred during the period from April 2013 through June 2014. During that period, SMMG received approximately $55,000 for its efforts. Neither SMMG nor anyone associated with it own shares in Plandai Biotechnology. For more information: www.stockmarketmediagroup.com.
Stock Market Media Group